Active substance
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TOVIAZ | 4MG; 8MG | tablet, extended release · oral | PFIZER | Prescription | 31 Oct 2008 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | ALKEM LABS LTD | Prescription | 10 Dec 2015 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | AUROBINDO PHARMA | Prescription | 17 Feb 2017 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | ZYDUS PHARMS | Prescription | 3 Oct 2017 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | DR REDDYS | Prescription | 13 Aug 2019 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | ALEMBIC | Prescription | 4 Jan 2023 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | AMNEAL PHARMS NY | Prescription | 4 Jan 2023 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | HETERO LABS LTD V | Prescription | 9 Jan 2024 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | ANI PHARMS | Discontinued | 4 Jan 2023 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | ACTAVIS LABS FL INC | Discontinued | 4 Jan 2023 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | ACCORD HLTHCARE | Discontinued | 4 Jan 2023 |
| FESOTERODINE FUMARATE | 4MG; 8MG | tablet, extended release · oral | CHARTWELL RX | Discontinued | 5 Jan 2023 |
Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACH-FESOTERODINE | 02535998 | 4 MG | TABLET (EXTENDED-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACH-FESOTERODINE | 02536005 | 8 MG | TABLET (EXTENDED-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| SANDOZ FESOTERODINE FUMARATE | 02521768 | 4 MG | TABLET (EXTENDED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ FESOTERODINE FUMARATE | 02521776 | 8 MG | TABLET (EXTENDED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
| TOVIAZ | 02380021 | 4 MG | TABLET (EXTENDED-RELEASE) · ORAL | PFIZER CANADA ULC |
| TOVIAZ | 02380048 | 8 MG | TABLET (EXTENDED-RELEASE) · ORAL | PFIZER CANADA ULC |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FESOTERODINE ER 4 MG TABLET | $0.7938 | per EA | 23 Sep 2026 |
| US NADAC | FESOTERODINE ER 8 MG TABLET | $0.8393 | per EA | 23 Sep 2026 |
| US NADAC | TOVIAZ ER 4 MG TABLET | $9.27825 | per EA | 23 Sep 2026 |
| US NADAC | TOVIAZ ER 8 MG TABLET | $9.26235 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Fesoterodine 4mg modified-release tablets | £8.16 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Fesoterodine 8mg modified-release tablets | £8.27 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.